The chronic spontaneous urticaria market is witnessing significant growth, driven by increasing disease awareness, improved diagnosis rates, and the rising prevalence of treatment-refractory patients. The introduction of emerging therapies such as Barzolvolimab (CDX-0159) (Celldex Therapeutics), Rilzabrutinib (Sanofi), Briquilimab (Jasper Therapeutics), EVO756 (Evommune), and others will further propel the market growth.. 慢性自发性荨麻疹市场正经历显著增长，这得益于疾病认知度的提高、诊断率的改善以及难治性患者患病率的上升。Barzolvolimab（CDX-0159）（Celldex Therapeutics）、Rilzabrutinib（赛诺菲）、Briquilimab（Jasper Therapeutics）、EVO756（Evommune）等新兴疗法的推出将进一步推动市场增长。LAS VEGAS 拉斯维加斯, ，June 24, 2026 2026年6月24日/PRNewswire/ --Recently published Chronic Spontaneous Urticaria Market Insights report includes a comprehensive understanding of current treatment practices, chronic spontaneous urticaria emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].. /美通社/ -- 最近发布的《慢性自发性荨麻疹市场洞察》报告全面解析了当前的治疗实践、慢性自发性荨麻疹新兴药物、各疗法的市场份额，以及2022年至2036年期间的当前和预测市场规模，并按主要市场（美国、欧盟四国（德国、法国、意大利和西班牙）、英国和日本）进行了细分。Chronic Spontaneous Urticaria Market Summary 慢性自发性荨麻疹市场概况The total market size of chronic spontaneous urticaria in the 7MM in 2025 was approximately 2025年，七大主要市场慢性自发性荨麻疹的总市场规模约为USD 2 billion 20亿美元. 。The United States accounted for the largest chronic spontaneous urticaria treatment market size in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan. 2025年，美国在全球慢性自发性荨麻疹治疗市场中占据最大份额，远超其他主要市场，包括欧盟四国（德国、法国、意大利和西班牙）、英国和日本。The total diagnosed prevalent cases of chronic urticaria in the 7MM were approximately 七大主要市场慢性荨麻疹的总确诊患病人数约为4.8 million 480万in 2025, with these numbers anticipated to increase by 2036. 2025年，预计这些数字到2036年将有所增加。Leading chronic spontaneous urticaria companies, such as 慢性自发性荨麻疹领域的领先企业，例如Celldex Therapeutics, Sanofi, Jasper Therapeutics, Evommune, Blueprint Medicines, ARS Pharmaceuticals, Nurix Therapeutics, InflaRx, Otsuka Holdings (Taiho Pharmaceutical), Celldex Therapeutics，赛诺菲，Jasper Therapeutics，Evommune，Blueprint Medicines，ARS Pharmaceuticals，Nurix Therapeutics，InflaRx，大冢控股（大正制药），and others, are developing new chronic spontaneous urticaria treatment drugs that can be available in the chronic spontaneous urticaria market in the coming years. 以及其他公司正在开发新的慢性自发性荨麻疹治疗药物，这些药物有望在未来几年内上市。The promising chronic spontaneous urticaria therapies in clinical trials include 临床试验中前景良好的慢性自发性荨麻疹疗法包括Barzolvolimab (CDX-0159), Rilzabrutinib, Briquilimab, EVO756, BLU-808, ARS -1, bexobrutideg (NX-5948), INF904, TAS5315, 巴佐伏利单抗（CDX-0159）、利扎布鲁替尼、布里基利单抗、EVO756、BLU-808、ARS-1、贝索布鲁替德（NX-5948）、INF904、TAS5315，and others. 以及其他。Discover the chronic spontaneous urticaria treatments with best digital health tools @ 探索利用最佳数字健康工具治疗慢性自发性荨麻疹的方法 @http://delveinsight.com/report-store/chronic-spontaneous-urticaria-market http://delveinsight.com/report-store/chronic-spontaneous-urticaria-marketKey Factors Driving the Growth of the Chronic Spontaneous Urticaria Market 推动慢性自发性荨麻疹市场增长的关键因素Growing Chronic Spontaneous Urticaria Prevalence: 慢性自发性荨麻疹患病率不断上升：According to DelveInsight's estimates, the total diagnosed prevalent cases of chronic urticaria in the 7MM were approximately 根据 DelveInsight 的估算，7MM 中慢性荨麻疹的确诊患病总病例数约为4.8 million 480万in 2025, with these numbers anticipated to increase by 2036. 2025年，预计这些数字到2036年将有所增长。DUPIXENT's Monopoly in the CSU Market: DUPIXENT在慢性自发性荨麻疹（CSU）市场的垄断地位：The recent approval of DUPIXENT (dupilumab) by the US FDA, along with its earlier approval in Japan by the MHLW, marks a notable shift in the treatment landscape, introducing targeted therapies that are likely to drive market competition and influence the adoption. 美国食品药品监督管理局（FDA）近期批准DUPIXENT（度普利尤单抗），加之此前日本厚生劳动省（MHLW）的批准，标志着治疗格局发生显著转变，引入了靶向疗法，这可能会推动市场竞争并影响其临床应用。Advancements in Patient-Friendly Treatment Delivery: 患者友好型治疗给药技术的进展：Improved delivery formats, such as oral small molecules like BTK inhibitors and potential JAK inhibitors, offer alternatives to injections, enhancing patient convenience and treatment adherence. 改进的给药形式，如布鲁顿酪氨酸激酶（BTK）抑制剂等口服小分子药物以及潜在的JAK抑制剂，为注射治疗提供了替代方案，从而提高了患者的便利性和治疗依从性。Growing CSU Clinical Trial Activity: 不断增长的CSU临床试验活动：The CSU treatment pipeline is increasingly competitive, featuring several promising candidates at different stages of development, including 慢性自发性荨麻疹（CSU）治疗管线竞争日益激烈，涵盖处于不同开发阶段的多个潜力候选药物，包括Barzolvolimab (CDX-0159) 巴佐沃利单抗（CDX-0159）(Celldex Therapeutics), （Celldex Therapeutics），Rilzabrutinib 利扎布鲁替尼(Sanofi), （赛诺菲）Briquilimab Briquilimab(Jasper Therapeutics), （贾斯珀治疗公司）EVO756 EVO756(Evommune), (Evommune),BLU-808 BLU-808(Blueprint Medicines), （蓝图医药）ARS -1 ARS -1(ARS Pharmaceuticals), bexobrutideg (NX-5948), （ARS Pharmaceuticals），bexobrutideg（NX-5948），bexobrutideg (NX-5948) 贝索布替尼（NX-5948）(Nurix Therapeutics), （Nurix Therapeutics）INF904 INF904(InflaRx), （InflaRx）TAS5315 TAS5315[Otsuka Holdings (Taiho Pharmaceutical)], and others. [大冢控股（大正制药）] 等。Ramandeep Singh, senior consultant of forecasting at DelveInsight, said that advancements in biologic therapies, such as omalizumab, have shown strong efficacy in antihistamine-refractory CSU, providing targeted and effective options for difficult-to-treat patients. DelveInsight 高级预测顾问 Ramandeep Singh 表示，奥马珠单抗等生物制剂疗法的进展在抗组胺药难治性慢性自发性荨麻疹（CSU）中显示出显著疗效，为难治性患者提供了靶向且有效的治疗选择。Chronic Spontaneous Urticaria Market Analysis 慢性自发性荨麻疹市场分析Managing chronic spontaneous urticaria remains complex, with treatment goals centered on reducing disease activity, achieving complete symptom relief, and enhancing patients' quality of life (QoL). 慢性自发性荨麻疹的管理仍然复杂，治疗目标集中在减少疾病活动性、实现完全症状缓解以及提高患者的生活质量（QoL）。Current management follows a stepwise strategy, beginning with first-line therapies and escalating to more advanced interventions when adequate disease control is not achieved. 目前的管理遵循阶梯式策略，从一线治疗开始，若未能实现充分的疾病控制，则逐步升级至更先进的干预措施。While existing treatments such as high-dose H1-antihistamines and anti-IgE therapy with omalizumab have improved outcomes, a substantial proportion of patients continue to experience persistent symptoms, underscoring the need for additional therapeutic options. 尽管现有治疗方法（如高剂量H1抗组胺药和奥马珠单抗的抗IgE治疗）已改善了疗效，但仍有相当比例的患者持续存在症状，这凸显出对更多治疗选择的需求。The recent approvals of 最近批准的DUPIXENT (dupilumab) and RHAPSIDO (remibrutinib) 达必妥（度普利尤单抗）和 RHAPSIDO（雷米布替尼）, a highly selective Bruton's tyrosine kinase (BTK) inhibitor, have broadened the treatment landscape beyond traditional anti-IgE biologics. ，一种高选择性的布鲁顿酪氨酸激酶（BTK）抑制剂，已经拓宽了传统抗IgE生物制剂之外的治疗领域。Furthermore, the CSU pipeline remains robust and competitive, with several promising investigational therapies, including 此外，CSU 研发管线依然稳健且具备竞争力，拥有多种前景广阔的在研疗法，包括barzolvolimab (CDX-0159), rilzabrutinib, briquilimab 巴佐沃利单抗（CDX-0159）、利扎布鲁替尼、布里基利单抗, and others advancing through clinical development and offering potential new avenues for disease management. ，以及其他正在通过临床开发并为疾病管理提供潜在新途径的药物。Chronic Spontaneous Urticaria Competitive Landscape 慢性自发性荨麻疹竞争格局Some of the CSU drugs under development include 正在开发的一些CSU药物包括Barzolvolimab (CDX-0159) 巴佐伏利单抗（CDX-0159）(Celldex Therapeutics), (Celldex Therapeutics),Rilzabrutinib 里扎布鲁替尼(Sanofi), （赛诺菲）Briquilimab Briquilimab(Jasper Therapeutics), （贾斯珀治疗公司）EVO756 EVO756(Evommune), （Evommune）BLU-808 BLU-808(Blueprint Medicines), （蓝图医药）ARS -1 ARS -1(ARS Pharmaceuticals), bexobrutideg (NX-5948), (ARS Pharmaceuticals)，bexobrutideg (NX-5948)，bexobrutideg (NX-5948) 贝索布鲁替德（NX-5948）(Nurix Therapeutics), （Nurix Therapeutics）INF904 INF904(InflaRx), （InflaRx）TAS5315 TAS5315[Otsuka Holdings (Taiho Pharmaceutical)], and others. [大冢控股（大正制药）] 等。Celldex Therapeutics' Barzolvolimab Celldex Therapeutics公司的Barzolvolimabis a humanized monoclonal antibody designed to specifically inhibit KIT, a receptor tyrosine kinase essential for mast cell growth, activation, and migration into tissues. Given the central role of mast cells in the inflammatory processes underlying chronic spontaneous urticaria (CSU), targeting KIT represents a promising strategy for disease management.. 是一种人源化单克隆抗体，旨在特异性抑制KIT（一种对肥大细胞的生长、活化及向组织迁移至关重要的受体酪氨酸激酶）。鉴于肥大细胞在慢性自发性荨麻疹（CSU）潜在炎症过程中的核心作用，靶向KIT代表了一种极具前景的疾病管理策略。Sanofi's Rilzabrutinib 赛诺菲的Rilzabrutinibis an orally administered, reversible covalent inhibitor of Bruton's tyrosine kinase (BTK) being developed as a potential first- or best-in-class treatment for a range of immune-mediated disorders. By selectively targeting BTK, a key signaling molecule found in both B cells and mast cells that regulates immune responses, rilzabrutinib utilizes Sanofi's proprietary TAILORED COVALENCY technology to enhance target specificity while reducing unintended effects on other pathways.. 是一种口服给药的可逆共价Bruton酪氨酸激酶（BTK）抑制剂，正在开发中，有望成为治疗多种免疫介导疾病的首创或同类最佳药物。通过选择性靶向BTK（一种存在于B细胞和肥大细胞中、调节免疫反应的关键信号分子），rilzabrutinib利用赛诺菲专有的TAILORED COVALENCY技术，在提高靶点特异性的同时减少对其他通路的非预期影响。Jasper Therapeutics' Briquilimab Jasper Therapeutics 的 Briquilimabis an investigational monoclonal antibody currently in Phase Ib/IIa development that targets the stem cell factor (SCF)/CD117 (c-Kit) signaling axis, which is critical for mast cell maintenance. By preventing the interaction between SCF and CD117, briquilimab aims to deplete mast cells in affected tissues, potentially providing therapeutic benefit to CSU patients who do not achieve adequate symptom control with antihistamine therapy.. 是一种处于Ib/IIa期开发阶段的在研单克隆抗体，靶向对肥大细胞维持至关重要的干细胞因子（SCF）/CD117（c-Kit）信号轴。通过阻止SCF与CD117之间的相互作用，briquilimab旨在清除受累组织中的肥大细胞，从而可能为那些经抗组胺药治疗未能充分控制症状的慢性自发性荨麻疹（CSU）患者提供治疗获益。The anticipated launch of these emerging therapies are poised to transform the chronic spontaneous urticaria market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the chronic spontaneous urticaria market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.. 这些新兴疗法的预期上市将在未来几年改变慢性自发性荨麻疹市场的格局。随着这些前沿疗法不断成熟并获得监管批准，预计它们将重塑慢性自发性荨麻疹市场格局，提供新的护理标准，并为医疗创新和经济增长带来机遇。Discover more about the most effective treatment options for chronic spontaneous urticaria @ 了解更多关于慢性自发性荨麻疹最有效的治疗方案 @Chronic Spontaneous Urticaria Treatment Guidelines 2026 2026年慢性自发性荨麻疹治疗指南Recent Developments in the Chronic Spontaneous Urticaria Market 慢性自发性荨麻疹市场的最新进展In 在May 2026, Nurix Therapeutics 2026年5月，Nurix Therapeuticsreported new preclinical and Phase 1 translational findings demonstrating the potential of bexobrutideg (NX-5948), its wholly owned Bruton's tyrosine kinase (BTK) degrader, as a treatment for chronic spontaneous urticaria (CSU). The results were presented at the 2026 Society for Investigative Dermatology Annual Meeting 2026 held in Chicago, Illinois.. 报告了新的临床前和I期转化研究结果，展示了其全资拥有的布鲁顿酪氨酸激酶（BTK）降解剂bexobrutideg（NX-5948）作为慢性自发性荨麻疹（CSU）治疗药物的潜力。该结果在伊利诺伊州芝加哥举行的2026年调查皮肤病学会年会上公布。In 在April 2026, 2026年4月，the FDA approved DUPIXENT (dupilumab) for treating children aged 2–11 years with chronic spontaneous urticaria who continue to experience symptoms despite treatment with histamine-1 antihistamines (H1AHs). The approval broadens Dupixent's existing indication, which previously covered adults and adolescents aged 12 years and older with CSU.. 美国食品药品监督管理局（FDA）批准DUPIXENT（度普利尤单抗）用于治疗2至11岁慢性自发性荨麻疹儿童患者，这些患者在接受组胺-1抗组胺药（H1AHs）治疗后症状仍持续存在。此次批准扩大了Dupixent的现有适应症，此前其适应症仅涵盖12岁及以上的慢性自发性荨麻疹成人和青少年患者。In 在March 2026, Celldex 2026年3月，Celldexunveiled further encouraging results from completed Phase 2 studies of barzolvolimab in CSU, ColdU, and SD, showing marked improvements in patient quality of life across all assessed areas, including symptom relief, emotional well-being, everyday activities, leisure pursuits, workplace and academic performance, interpersonal relationships, and treatment experience.. 公布了巴佐利沃单抗（barzolvolimab）在慢性自发性荨麻疹（CSU）、寒冷性荨麻疹（ColdU）和症状性皮肤病（SD）中已完成的2期临床试验的更多积极结果，显示患者在所有评估领域（包括症状缓解、情绪健康、日常活动、休闲活动、工作和学业表现、人际关系以及治疗体验）的生活质量均有显著改善。In 在January 2026, Jasper Therapeutics 2026年1月，Jasper Therapeuticsreported updated results from the Phase Ib/IIa BEACON study and its open-label extension showing that briquilimab delivered sustained disease control in CSU. Additional patients achieved complete responses and marked reductions in UAS7 scores at 12 weeks. 报告了Ib/IIa期BEACON研究及其开放标签扩展研究的更新结果，显示briquilimab在慢性自发性荨麻疹（CSU）中实现了持续的疾病控制。更多患者在12周时达到完全缓解，且UAS7评分显著降低。What is Chronic Spontaneous Urticaria? 什么是慢性自发性荨麻疹？Chronic spontaneous urticaria (CSU) is a chronic inflammatory skin disorder characterized by the recurrent appearance of itchy wheals (hives), angioedema, or both, occurring spontaneously without an identifiable external trigger for six weeks or longer. The condition is driven by the activation of mast cells and basophils, which release histamine and other inflammatory mediators, leading to redness, swelling, and intense itching. 慢性自发性荨麻疹（CSU）是一种慢性炎症性皮肤病，其特征为反复发作的风团（荨麻疹）、血管性水肿或两者兼有，且在六周或更长时间内自发出现，无明确的外部诱因。该病由肥大细胞和嗜碱性粒细胞活化驱动，这些细胞释放组胺和其他炎症介质，导致红斑、肿胀和剧烈瘙痒。CSU can significantly impair patients' quality of life by disrupting sleep, daily activities, work productivity, and emotional well-being. Although the exact cause remains unclear, autoimmune mechanisms are believed to play a key role in many patients. The disease affects individuals of all ages and often requires long-term management with antihistamines, biologics, or other targeted therapies to control symptoms and prevent recurrence.. 慢性自发性荨麻疹（CSU）可通过干扰睡眠、日常活动、工作效率和情绪健康，显著降低患者的生活质量。尽管确切病因尚不明确，但人们认为自身免疫机制在许多患者中起着关键作用。该病可影响各个年龄段的人群，通常需要通过抗组胺药、生物制剂或其他靶向疗法进行长期管理，以控制症状并预防复发。Chronic Spontaneous Urticaria Epidemiology Segmentation 慢性自发性荨麻疹流行病学细分The chronic spontaneous urticaria epidemiology section provides insights into the historical and current chronic spontaneous urticaria patient pool and forecasted trends for the leading markets. Among the 7MM, the US accounted for nearly 慢性自发性荨麻疹流行病学部分提供了对主要市场历史及当前慢性自发性荨麻疹患者群体规模以及预测趋势的深入分析。在七大市场中，美国占据了近19% 19%of the total diagnosed prevalent cases of chronic urticaria, with around 占慢性荨麻疹总确诊患病病例的，其中约920,000 920,000cases in 2025. 2025年的案件。The chronic spontaneous urticaria treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into: 慢性自发性荨麻疹治疗市场报告提供了2022年至2036年研究期间在主要市场的流行病学分析，细分如下：Total Diagnosed Prevalent Cases of Chronic Urticaria 慢性荨麻疹的总确诊患病病例数Type-specific Cases of Chronic Urticaria 慢性荨麻疹的特定类型病例Gender-specific Cases of CSU 慢性自发性荨麻疹的性别特异性病例Age-specific Cases of CSU 慢性自发性荨麻疹的年龄别病例数Severity-specific Cases of CSU 慢性自发性荨麻疹的严重程度特异性病例Chronic Spontaneous Urticaria Market Report Metrics 慢性自发性荨麻疹市场报告指标Details 详情Study Period 学习周期2022–2036 2022–2036Coverage 覆盖范围7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. 7MM [美国、欧盟四国（德国、法国、意大利和西班牙）、英国和日本]。Chronic Spontaneous Urticaria Epidemiology Segmentation 慢性自发性荨麻疹流行病学细分Total Diagnosed Prevalent Cases of Chronic Urticaria, Type-specific Cases of Chronic Urticaria, Gender-specific Cases of CSU, Age-specific Cases of CSU, and Severity-specific Cases of CSU 慢性荨麻疹的总诊断患病病例数、按类型划分的慢性荨麻疹病例数、按性别划分的慢性自发性荨麻疹（CSU）病例数、按年龄划分的CSU病例数以及按严重程度划分的CSU病例数Chronic Spontaneous Urticaria Market Size in 2025 2025年慢性自发性荨麻疹市场规模USD 2 Billion 20亿美元Key Chronic Spontaneous Urticaria Companies 慢性自发性荨麻疹领域的主要企业Celldex Therapeutics, Sanofi, Jasper Therapeutics, Evommune, Blueprint Medicines, ARS Pharmaceuticals, Nurix Therapeutics, InflaRx, Otsuka Holdings (Taiho Pharmaceutical), Regeneron Pharmaceuticals, Novartis, and others Celldex Therapeutics、赛诺菲、Jasper Therapeutics、Evommune、Blueprint Medicines、ARS Pharmaceuticals、Nurix Therapeutics、InflaRx、大冢控股（Taiho Pharmaceutical）、再生元制药、诺华等Key Chronic Spontaneous Urticaria Therapies 慢性自发性荨麻疹的关键疗法Barzolvolimab (CDX-0159), Rilzabrutinib, Briquilimab, EVO756, BLU-808, ARS -1, bexobrutideg (NX-5948), INF904, TAS5315, DUPIXENT, RHAPSIDO, and others Barzolvolimab (CDX-0159)、Rilzabrutinib、Briquilimab、EVO756、BLU-808、ARS-1、bexobrutideg (NX-5948)、INF904、TAS5315、DUPIXENT、RHAPSIDO 等Scope of the 范围Chronic Spontaneous Urticaria 慢性自发性荨麻疹Market Report 市场报告Chronic Spontaneous Urticaria Patient Population Forecast 慢性自发性荨麻疹患者人群预测Chronic Spontaneous Urticaria Therapeutics Market Size 慢性自发性荨麻疹治疗市场Chronic Spontaneous Urticaria Pipeline Analysis 慢性自发性荨麻疹管线分析Chronic Spontaneous Urticaria Market Size and Trends 慢性自发性荨麻疹市场规模与趋势Chronic Spontaneous Urticaria Market Opportunity 慢性自发性荨麻疹市场机遇Chronic Spontaneous Urticaria Market Unmet Needs 慢性自发性荨麻疹市场的未满足需求KOL's Views on Chronic Spontaneous Urticaria 关键意见领袖对慢性自发性荨麻疹的观点Chronic Spontaneous Urticaria Market Access and Reimbursement 慢性自发性荨麻疹的市场准入与报销Download the report to understand the average treatment costs chronic spontaneous urticaria @ 下载报告以了解慢性自发性荨麻疹的平均治疗费用 @Chronic Spontaneous Urticaria Treatments Cost and Coverage 慢性自发性荨麻疹治疗的费用与保险覆盖范围Table of Contents 目录1 1Chronic Spontaneous Urticaria Market Key Insights 慢性自发性荨麻疹市场关键洞察2 2Chronic Spontaneous Urticaria Market Report Introduction 慢性自发性荨麻疹市场报告简介3 3CSU Market Overview at a Glance CSU市场概览一览3.1 3.1Market Share (%) Distribution of CSU by Therapies in the 7MM in 2025 2025年七国市场（7MM）中按疗法划分的慢性自发性荨麻疹（CSU）市场份额（%）分布3.2 3.2Market Share (%) Distribution of CSU by Therapies in the 7MM in 2036 2036年七国市场（7MM）中按疗法划分的慢性自发性荨麻疹（CSU）市场份额（%）分布4 4Executive Summary 执行摘要5 5Key Events 关键事件6 6Disease Background and Overview 疾病背景与概述6.1 6.1Introduction 引言6.2 6.2Signs and symptoms 体征和症状6.3 6.3Classification 分类6.4 6.4Causes 原因6.5 6.5Pathophysiology 病理生理学6.6 6.6Clinical Manifestation 临床表现6.7 6.7Diagnosis 诊断6.8 6.8Treatment and Management 治疗与管理7 7Methodology 方法论8 8Epidemiology and Patient Population 流行病学与患者人群8.1 8.1Key Findings 主要发现8.2 8.2Assumptions and Rationale: The 7MM 假设与依据：7MM8.2.1 8.2.1Diagnosed Prevalent Cases of Chronic Urticaria 慢性荨麻疹的确诊现患病例8.2.2 8.2.2Type-specific Cases of Chronic Urticaria 慢性荨麻疹的特定类型病例8.2.3 8.2.3Gender-specific Cases of CSU 慢性自发性荨麻疹的性别特异性病例8.2.4 8.2.4Age-specific Cases of CSU 慢性自发性荨麻疹的年龄别病例数8.2.5 8.2.5Severity-specific Cases of CSU 按严重程度分类的慢性自发性荨麻疹病例8.3 8.3Total Diagnosed Prevalent Cases of CSU in the 7MM 7MM中慢性自发性荨麻疹（CSU）的确诊患病总病例数8.4 8.4The US 美国8.5 8.5EU4 and the UK 欧盟四国与英国8.6 8.6Japan 日本9 9Patient Journey 患者旅程10 10Marketed Chronic Spontaneous Urticaria Drugs 已上市的慢性自发性荨麻疹药物10.1 10.1DUPIXENT (dupilumab): Sanofi/Regeneron Pharmaceuticals 达必妥（度普利尤单抗）：赛诺菲/再生元制药10.1.1 10.1.1Product Description 产品描述10.1.2 10.1.2Regulatory Milestones 监管里程碑10.1.3 10.1.3Other Developmental Activities 其他发展活动10.1.4 10.1.4Clinical Trials Information 临床试验信息10.1.5 10.1.5Safety and Efficacy 安全性与有效性10.2 10.2RHAPSIDO (remibrutinib): Novartis RHAPSIDO（瑞米布替尼）：诺华List to be continued in the final report.. 列表将在最终报告中继续列出。11 十一Emerging Chronic Spontaneous Urticaria Drugs 新兴的慢性自发性荨麻疹药物11.1 11.1Key Cross Competition 关键交叉竞争11.2 11.2Barzolvolimab (CDX-0159): Celldex Therapeutics Barzolvolimab（CDX-0159）：Celldex Therapeutics11.2.1 11.2.1Drug Description 药物说明11.2.2 11.2.2Other Developmental Activities 其他发展活动11.2.3 11.2.3Clinical Trials Information 临床试验信息11.2.4 11.2.4Safety and Efficacy 安全性与有效性11.2.5 11.2.5Analysts' View 分析师观点11.3 11.3Rilzabrutinib: Sanofi 利扎布替尼：赛诺菲11.4 11.4Briquilimab: Jasper Therapeutics Briquilimab：Jasper Therapeutics11.5 11.5INF904: InflaRx INF904：InflaRx11.6 11.6EVO756: Evommune EVO756：Evommune11.7 11.7TAS5315: Otsuka Holdings (Taiho Pharmaceutical) TAS5315：大冢控股（大正制药）List to be continued in the final report.. 列表将在最终报告中继续。12 12CSU Market – 7MM Market Analysis CSU市场 – 7MM市场分析12.1 12.1Key Findings 主要发现12.2 12.2Chronic Spontaneous Urticaria Market Outlook 慢性自发性荨麻疹市场展望12.3 12.3Attribute Analysis 属性分析12.4 12.4Key Chronic Spontaneous Urticaria Market Forecast Assumptions 慢性自发性荨麻疹市场预测的关键假设12.5 12.5Total Market Size of CSU in the 7MM 7MM国家CSU市场总规模12.6 12.6Market Size of CSU by Therapies in the 7MM 七国市场（7MM）按疗法划分的慢性自发性荨麻疹（CSU）市场规模12.7 12.7The US Chronic Spontaneous Urticaria Market 美国慢性自发性荨麻疹市场12.7.1 12.7.1Total Market Size of CSU in the US 美国CSU的总市场规模12.7.2 12.7.2Market Size of CSU by Therapies in the US 美国按疗法划分的慢性自发性荨麻疹（CSU）市场规模12.8 12.8EU4 and the UK Chronic Spontaneous Urticaria Market 欧盟四国及英国慢性自发性荨麻疹市场12.9 12.9Japan Chronic Spontaneous Urticaria Market 日本慢性自发性荨麻疹市场13 13Key Opinion Leaders' Views 关键意见领袖的观点14 十四Unmet Needs 未满足的需求15 十五SWOT Analysis SWOT分析16 16Chronic Spontaneous Urticaria Market Access and Reimbursement 慢性自发性荨麻疹的市场准入与报销16.1 16.1The United States 美国16.2 16.2EU4 and the UK 欧盟四国与英国16.3 16.3Japan 日本17 十七Acronyms and Abbreviations 首字母缩略词和缩写18 18Bibliography 参考文献19 十九Chronic Spontaneous Urticaria Market Report Methodology 慢性自发性荨麻疹市场报告方法论Related Reports 相关报告BTK Inhibitors Market BTK抑制剂市场BTK Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast BTK抑制剂市场规模、目标人群、竞争格局与市场预测– –2034 2034report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key BTK inhibitors companies, including 报告深入剖析市场趋势、市场驱动因素、市场壁垒以及主要的BTK抑制剂企业，包括BeiGene, Nurix Therapeutics, Roche, Genentech, Sanofi, Principia Pharma, Novartis, ACEA Therapeutics, InnoCare Pharma, 百济神州、Nurix Therapeutics、罗氏、基因泰克、赛诺菲、Principia Pharma、诺华、ACEA Therapeutics、诺诚健华，and others. 以及其他。Chronic Spontaneous Urticaria Clinical Trial Analysis 慢性自发性荨麻疹临床试验分析Chronic Spontaneous Urticaria Pipeline Insight – 2026 慢性自发性荨麻疹研发管线洞察 – 2026report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic spontaneous urticaria companies, including 本报告提供关于管线格局、管线药物概况（包括临床和非临床阶段产品）以及慢性自发性荨麻疹领域关键企业的全面洞察，包括United BioPharma, Teva Pharmaceuticals Development, Inc., Amgen, Novartis Pharmaceuticals, Allakos Inc., Sanofi, Celltrion, Celldex Therapeutics, MICROBIO GROUP., Escient Pharmaceuticals, Jasper Therapeutics, Glenmark Pharmaceuticals, Taiho Pharmaceuticals, ValenzaBio, Carna Biosciences, Servier, 联合生物制药公司、梯瓦制药开发公司、安进、诺华制药、阿拉科斯公司、赛诺菲、Celltrion、Celldex治疗公司、MICROBIO集团、Escient制药公司、Jasper治疗公司、Glenmark制药公司、大保制药、ValenzaBio、Carna生物科学公司、Servier，and others. 以及其他。Chronic Inducible Urticaria Market 慢性诱导性荨麻疹市场Chronic Inducible Urticaria Market Insights, Epidemiology, and Market Forecast – 2034 慢性诱导性荨麻疹市场洞察、流行病学及市场预测 – 2034report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key chronic inducible urticaria companies including 本报告提供对疾病的深入洞察，包括历史及预测流行病学数据，以及市场趋势、市场驱动因素、市场壁垒和慢性诱导性荨麻疹领域的主要企业，其中包括Sanofi, Allakos Inc., Celldex Therapeutics, 赛诺菲、Allakos公司、Celldex治疗公司，and others. 以及其他。Chronic Inducible Urticaria Clinical Trial Analysis 慢性诱导性荨麻疹临床试验分析Chronic Inducible Urticaria Pipeline Insight – 2026 慢性诱导性荨麻疹研发管线洞察 – 2026report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic inducible urticaria companies, including 报告提供了关于管线格局、管线药物概况（包括临床和非临床阶段产品）以及慢性诱导性荨麻疹领域关键企业的全面洞察，包括Celldex Therapeutics, Jasper Therapeutics, Celldex Therapeutics，Jasper Therapeutics，and others. 以及其他。Urticaria Pipeline 荨麻疹研发管线Urticaria Pipeline Insight – 2026 荨麻疹研发管线洞察 – 2026report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key urticaria companies, including 报告提供了关于管线格局、管线药物概况（包括临床和非临床阶段产品）以及关键荨麻疹公司的全面洞察，包括Regeneron Pharmaceuticals, Taiho Pharmaceutical Co., Ltd, Allakos Inc, Yuhan Corporation, United BioPharma, Hangzhou Highlightll Pharmaceutical Co., Ltd, Kiniksa Pharmaceuticals, Ltd., Celldex Therapeutics, Longbio Pharma, Celltrion, Enanta Pharmaceuticals, 再生元制药公司、大鵬药品工业株式会社、Allakos公司、柳韩洋行、联合生物制药公司、杭州海特药业股份有限公司、Kiniksa制药有限公司、Celldex治疗公司、龙波制药、Celltrion公司、Enanta制药公司，among others. 以及其他。About 关于DelveInsight DelveInsightDelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platformPharmDelve. DelveInsight 是一家领先的商业咨询和市场研究公司，专注于生命科学领域。它通过提供全面的端到端解决方案来帮助制药公司提升绩效。通过我们基于订阅的平台 PharmDelve，您可以轻松获取所有医疗保健和制药市场研究报告。. 。Contact Us 联系我们Shruti Thakur 什鲁蒂·塔库尔[emailprotected] [email protected]+14699457679 +14699457679www.delveinsight.com www.delveinsight.comLogo: 标志：https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpgSOURCE DelveInsight Business Research, LLP 来源：DelveInsight Business Research, LLP21 二十一% %more press release views with 更多新闻稿浏览量，通过Request a Demo 申请演示
